Ask AI

When Blood Pressure Just Won’t Budge: Aldosterone and Hard-to-Control Hypertension From Mechanism to Management

Start Activity
Video
Video Start Activity
This activity is available for 1.50 CME/CE credit(s).

Released: October 30, 2026

Expiration: October 29, 2027

See Activity Collection

Step 1 of 5

1 Pre Assessment 2 Video 3 Post Assessment 4 Evaluation 5 Credit

Aldosterone plays a critical role in assessing and managing resistant hypertension because it contributes to patients’ disease progression and cardiorenal risk. Access this on-demand webcast to learn best practices for diagnosing resistant hypertension and applying the current evidence in your practice, including the development of patient-centered strategies that integrate aldosterone-targeted therapies for improved outcomes.

Debbie Cohen
Debbie Cohen, MD
John Flack
John Flack, MD, MPH, FAHA, FASH, MAC, CHS
Ty J. Gluckman
Ty J. Gluckman, MD, MHA
Resistant hypertension and aldosterone

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
Begin Your Video
1.

How many people with resistant HTN do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 62-yr-old man with T2D, stage 3a CKD, and resistant hypertension has BP 156/86 mm Hg despite amlodipine, chlorthalidone, and low-dose valsartan. Labs show K⁺ 3.6 mEq/L, eGFR 54, UACR 145 mg/g, high aldosterone, and suppressed renin; CT shows no adrenal mass.

Which strategy most directly targets the likely driver of his hypertension?

4.

A 59-yr-old patient with long-standing hypertension has an office BP of 152/88 mm Hg despite treatment with maximally tolerated doses of an ACE inhibitor, a calcium channel blocker, and a thiazide-type diuretic. Home BP readings are sometimes above goal.

Which statement best describes the clinical implications of this patient’s presentation regarding his persistent BP elevation despite 3-drug therapy?

5.

A 64-yr-old patient has hypertension despite maximally tolerated doses of an ARB, dihydropyridine calcium channel blocker, and a thiazide type diuretic. Office BP is 151/86 mm Hg, and home BP readings remain above goal. The patient has no symptoms, eGFR is 58 mL/min/1.73 m2, and serum potassium is 4.4 mmol/L. He says that he saw a commercial for a “new blood pressure medicine” with fewer adverse effects.

When would you consider baxdrostat in this patient’s management?

Begin Your Video